| RRC ID |
62061
|
| Author |
Imano M, Satou T, Itoh T, Yasuda A, Kato H, Shinkai M, Peng YF, Tsubaki M, Yasuda T, Imamoto H, Nishida S, Takeyama Y, Okuno K, Shiozaki H.
|
| Title |
Peritoneal metastatic lesions of gastric cancer exhibit low expression of human epidermal growth factor receptor 2.
|
| Journal |
Target Oncol
|
| Abstract |
The prognosis of gastric cancer patients with peritoneal metastasis is very poor. Recent findings suggest that use of trastuzumab, a monoclonal antibody-based agent that targets human epidermal growth factor receptor 2 (HER2), may improve the prognosis of gastric cancer patients with HER2 overexpression and/or gene amplification. However, whether these mechanisms of HER2 upregulation are present in gastric cancer patients with peritoneal metastasis is unclear. The status of HER2 expression in a cohort of samples obtained from 35 gastric cancer patients with peritoneal metastasis was investigated using immunohistochemistry and fluorescence in situ hybridization. In 18 cases, we also investigated the influence of induction chemotherapy on HER2 overexpression. The frequency of HER2 overexpression and gene amplification was 2.9 % (1/35) in peritoneal metastatic lesions. There was concurrence in HER2 status in the samples examined prior to and following induction of chemotherapy. Most samples from the gastric cancer patients with peritoneal metastasis did not show HER2 amplification and/or overexpression. Although our study size was small, these results suggest that trastuzumab, which is critically dependent on HER2 expression, might not be an effective agent for these patients. Consequently, other therapeutic approaches for these patients must be developed.
|
| Volume |
7(4)
|
| Pages |
213-6
|
| Published |
2012-12-1
|
| DOI |
10.1007/s11523-012-0223-z
|
| PMID |
22752927
|
| MeSH |
Adult
Aged
Female
Gene Expression Regulation, Neoplastic / drug effects
Humans
Induction Chemotherapy
Male
Middle Aged
Peritoneal Neoplasms / diagnosis*
Peritoneal Neoplasms / drug therapy*
Peritoneal Neoplasms / secondary
Prognosis
Receptor, ErbB-2 / genetics
Receptor, ErbB-2 / metabolism*
Stomach Neoplasms / diagnosis*
Stomach Neoplasms / drug therapy*
Stomach Neoplasms / pathology
Young Adult
|
| IF |
4.106
|
| Resource |
| Human and Animal Cells |
Vero(RCB0001)
AZ521(RCB2087)
MKN1(RCB1003)
MKN28(RCB1000)
MKN45(RCB1001)
MKN74(RCB1002) |
